This petition-letter addresses the ethical, medical, and financial practices of the Piramal Group, linking the continued marketing of Tetmosol (containing Monosulfiram) — an obsolete, unapproved, and potentially harmful dermatological product absent from global pharmacopoeia — with the structural injustices of the DHFL resolution that allegedly stripped ordinary depositors of their life savings. By highlighting toxicity concerns, regulatory loopholes, misleading advertisements, and the export of outdated drugs to vulnerable populations in the Global South, the letter frames Tetmosol as a metaphor for systemic exploitation: superficial relief masking deeper harm, profit extracted from public vulnerability, and corporate narratives of “conscious capitalism” greenwashing exploitation in both health and finance. It calls for urgent regulatory review by CDSCO, WHO, and international agencies, demands alignment with global treatment standards, and urges cross-sectoral accountability where medical and financial mis-selling are recognized as analogous public harms requiring restitution.